Acuity Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Acuity Pharmaceuticals is developing VEGF-directed RNAi-based therapeutics for ophthalmic diseases, including age-related wet macular degeneration and diabetic retinopathy.
You may also be interested in...
RNAi Enters the Clinic for Macular Degeneration
RNAi has quickly gained a stellar reputation for its utility as a research tool, but its potential to yield safe and effective drugs has yet to be proven. Acuity Pharmaceuticals took the industry's first step toward establishing a clinical foothold in October, when its Cand5 anti-VEGF siRNA entered Phase I trials in age-related macular degeneration (AMD). Sirna followed suit in late November with a Phase I trial of Sirna-027, its own siRNA targeting VEGFR-1. IP issues remain to be settled.
RNAi Enters the Clinic for Macular Degeneration
RNAi has quickly gained a stellar reputation for its utility as a research tool, but its potential to yield safe and effective drugs has yet to be proven. Acuity Pharmaceuticals took the industry's first step toward establishing a clinical foothold in October, when its Cand5 anti-VEGF siRNA entered Phase I trials in age-related macular degeneration (AMD). Sirna followed suit in late November with a Phase I trial of Sirna-027, its own siRNA targeting VEGFR-1. IP issues remain to be settled.
Eyetech Pharmaceuticals Inc.
Eyetech Pharmaceuticals believes that blocking angiogenesis is the best route to improved therapy for age-related macular degeneration and diabetic macular edema, degenerative conditions that frequently and quickly lead to serious vision loss and blindness. The company in-licensed a compound from Gilead Sciences, about to enter pivotal clinical trials, that it thinks does just that.